109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
OLIGONUCLEOTIDE MEDIATED NO-GO DECAY
#1502CARGO LOADED EXTRACELLULAR VESICLES
#1503OLIGONUCLEOTIDES FOR MSH3 MODULATION
#1504Sting-dependent activators for treatment of disease
#1505Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
#1506Substances for targeting various selected organs or tissues
#1507GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#1508Allele specific modulators of P23H rhodopsin
#1509Methods for reducing LRRK2 expression
#1510NON-CODING IMMUNOMODULATORY DNA CONSTRUCT
#1511Dual-acting siRNA based modulation of C9orf72
#1512Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof
#1513Oligonucleotides for tissue specific gene expression modulation
#1514ANTISENSE NUCLEIC ACIDS
#1515KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1516CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF
#1517Compositions and methods for increasing expression of SCN2A
#1518MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#1519Oligonucleotides for PRNP modulation
#1520Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide
#1521ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1522Nucleic Acid Compounds for Binding Immunoglobulin G
#1523USE OF A TLR9 AGONIST IN METHODS FOR TREATING COVID-19
#1524SERPINA1 iRNA compositions and methods of use thereof
#1525Compositions and methods for modulating neuronal excitability and motor behavior
#1526Compounds and Methods for Modulation of Transcript Processing
#1527PARN AS A BIOMARKER AND THERAPEUTIC TARGET
#1528Angiotensinogen (AGT) iRNA compositions and methods of use thereof
#1529CATIONIC COMPOUNDS FOR DELIVERY OF NUCLEIC ACIDS
#1530COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1531MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#1532MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#1533RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
#1534Compositions of Asymmetric Interfering RNA and Uses Thereof
#1535Compositions and methods of treating muscle dystrophy
#1536Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#1537Long double-stranded RNA for RNA interference
#1538ANTISENSE NUCLEIC ACIDS
#1539Methods for treating hepatitis B infection
#1540Methods and compositions for targeting PD-L1
#1541Compositions and methods for modulating PKK expression
#1542Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
#1543Compounds and methods for modulating UBE3A-ATS
#1544USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
#1545IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDS
#1546OLIGONUCLEOTIDE-BASED PROTEOLYSIS TARGETING CHIMERA
#1547Serpina1 iRNA compositions and methods of use thereof
#1548Compounds and methods for the modulation of proteins
#1549RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
#1550TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
#1551ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
#1552Complement component C3 iRNA compositions and methods of use thereof
#1553Modified compounds and uses thereof
#1554TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1555Oligonucleotide comprising an inosine for treating DMD
#1556SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1557OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1558LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
#1559Single-stranded oligonucleotide
#1560Compounds and methods for increasing STMN2 expression
#1561Antisense oligonucleotides and their use for treating Pendred syndrome
#1562Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
#1563Oligonucleotides for modulating SCN9A expression
#1564PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
#1565RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
#1566Oligonucleotide Conjugates
#1567Compositions and methods for improving strand biased
#1568Selective antisense compounds and uses thereof
#1569Nucleic acid-drug complex and use thereof
#1570OLIGONUCLEOTIDES FOR CONTROLLING TAU SPLICING, AND USES THEREOF
#1571Stereospecific linkages in RNA editing oligonucleotides
#1572Compositions for Modulating C9ORF72 Expression
#1573MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#1574POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#1575Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing
#1576ANTISENSE NUCLEIC ACIDS
#1577METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#1578LNA BASED NANODEVICE
#1579Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#1580COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS
#1581COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#1582Gamma herpesvirus circular RNA
#1583Compositions and methods for modulating growth hormone receptor expression
#1584Chirally-enriched double-stranded RNA agents
#1585Methods of Treating Celiac Disease Using SMAD7 Inhibition
#1586RNA-INTERFERENCE-INDUCING NUCLEIC ACID MOLECULE ABLE TO PENETRATE INTO CELLS, AND USE THEREFOR
#1587MYOCARDIAL DYSFUNCTION THERAPEUTIC AGENT
#1588APTAMER FOR SCLEROSTIN AND USE THEREOF
#1589ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#1590Antisense nucleic acids
#1591OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1592Method of allele specific silencing for the treatment of autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
#1593Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
#1594Composition for preventing or treating neurodegenerative disease
#1595S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
#1596Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
#1597COMPOSITIONS AND METHODS FOR MODULATING MONOCYTE AND MACROPHAGE INFLAMMATORY PHENOTYPES AND IMMUNOTHERAPY USES THEREOF
#1598Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1599C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE
#1600Transgene cassettes designed to express a human MECP2 gene
#1601Therapeutic inhibition of lactate dehydrogenase and agents therefor
#1602Compositions and methods for inhibiting gene expression of Hif2alpha
#1603Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#1604MODULATORS OF ENaC EXPRESSION
#1605Systems and methods for gene modification
#1606Compound for treatment of heart failure
#1607Nucleic acid-polypeptide compositions and uses thereof
#1608ANTISENSE NUCLEIC ACIDS
#1609Glucokinase (GCK) iRNA compositions and methods of use thereof
#1610Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1611Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1612METHODS OF MODULATING ANTISENSE ACTIVITY
#1613Polyanionic acids to improve recovery and minimize system loss
#1614Antisense nucleic acid targeting PCSK9
#1615Immunostimulatory compositions
#1616Modulation of factor 11 expression
#1617METHODS FOR REDUCING C9ORF72 EXPRESSION
#1618POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#1619METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#1620TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
#1621Modulation of alternative MDM2 splicing
#1622Agents useful in treating facioscapulohumeral muscular dystrophy
#1623AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1624COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
#1625Modulation of gene expression and screening for deregulated protein expression
#1626Modulators of EZH2 expression
#1627siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
#1628MYC NUCLEIC ACIDS AND USES THEREOF
#1629Gene editing methods with increased knock-in efficiency
#1630Methods for treating multiple sclerosis using antisense oligonucleotides
#1631OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#1632REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
#1633SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
#1634Selective Antisense Compounds and Uses Thereof
#1635Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#1636Oligonucleotides for reduction of PD-L1 expression
#1637RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#1638Oligonucleotide therapy for Leber congenital amaurosis
#1639Two-tailed self-delivering siRNA
#1640Modulation of Huntington expression
#1641Cancer chemoprevention with STAT3 blockers
#1642PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER
#1643Treatment of Fuchs' endothelial corneal dystrophy
#1644G-quadruplex-containing antisense oligonucleotides
#1645COMPOSITIONS AND METHODS
#1646Chiral control
#1647Gene Editing System and Gene Editing Method
#1648Modulators of YAP1 expression
#1649Sequence Multiplicity Within Spherical Nucleic Acids
#1650Oligonucleotides for modulating Tau expression
#1651Antisense oligonucleotides for the treatment of usher syndrome type 2
#1652POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#1653Nucleic acids for inhibiting expression of LPA in a cell
#1654Chiral design
#1655Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#1656O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
#1657Antisense oligonucleotides for the treatment of Stargardt disease
#1658MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#1659RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#1660MODULATORS OF GROWTH HORMONE RECEPTOR
#1661TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#1662OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF
#1663MicroRNA Compounds and Methods for Modulating MIR-122
#1664RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#1665Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#1666COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF
#1667BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY
#1668Compositions and methods for modulating MECP2 expression
#1669RNAi agents for hepatitis B virus infection
#1670Angiotensinogen (AGT) iRNA compositions and methods of use thereof
#1671Modified oligonucleotides for use in treatment of tauopathies
#1672Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
#1673Modulation of transthyretin expression
#1674ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1
#1675OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION
#1676OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
#1677Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction
#1678Compounds and methods for reducing FXI expression
#1679Modified Guide RNAs for Gene Editing
#1680Therapeutic oligonucleotides
#1681Compositions and methods for modulating apolipoprotein (a) expression
#1682Modulation of alpha synuclein expression
#1683Modulation of frataxin expression
#1684COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1685Modulators of PNPLA3 expression
#1686Anti-connexin compounds targeted to connexins and methods of use thereof
#1687Modulators of APOL1 expression
#1688Antisense oligonucleotide compositions
#1689GUIDE RNA WITH CHEMICAL MODIFICATIONS
#1690CLEAVAGE-RESISTANT DONOR NUCLEIC ACIDS AND METHODS OF USE
#1691Modulators of PCSK9 expression
#1692Compositions for modulating Tau expression
#1693METHODS OF PERFORMING GUIDE-SEQ ON PRIMARY HUMAN T CELLS
#1694Methods and compositions for inhibiting expression of LDHA
#1695Single stranded oligonucleotides inhibiting endocytosis
#1696Oligonucleotides for modulating TMEM106B expression
#1697Oligomers and oligomer conjugates
#1698CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#1699BIODIFFUSION CHAMBER
#1700CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#1701Compositions Comprising Immune System Activators and Method of Using Same
#1702Methods of treating spinal muscular atrophy
#1703Modified oligonucleotides and methods of use
#1704Antisense molecules and methods for treating pathologies
#1705Compounds and methods for the modulation of amyloid-β precursor protein
#1706IMMUNE CELL ACTIVATION
#1707Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#1708Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#1709Oligonucleotide therapy for Wilson disease
#1710Compositions and methods for modulation of SMN2 splicing in a subject
#1711Oligonucleotide compositions and methods thereof
#1712MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS
#1713Splice-switching oligonucleotides and methods of use
#1714Fully stabilized asymmetric siRNA
#1715COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1716TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES
#1717COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#1718Modified compounds and uses thereof
#1719Inhibition of polyomavirus replication
#1720Nucleic acid molecules for pseudouridylation
#1721Methods and compositions for modulating apolipoprotein (a) expression
#1722Methods for modulating FMR1 expression
#1723LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS
#1724Neurodegenerative disorders
#1725Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
#1726Selective antisense compounds and uses thereof
#1727COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1728Antisense oligonucleotides rescue aberrant splicing of ABCA4
#1729METHODS OF MODULATING ANTISENSE ACTIVITY
#1730Compositions and methods for enhancing reverse transcriptase activity and/or reducing the inhibition of reverse transcriptase
#1731Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1732ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#1733Treatment of angiopoietin like 7 (ANGPTL7) related diseases
#1734Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
#1735TMPRSS6 iRNA compositions and methods of use thereof
#1736MODULATORS OF DNM2 EXPRESSION
#1737Conjugated antisense compounds and their use
#1738Short interfering nucleic acid (siNA) compositions
#1739Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
#1740Compounds and methods for reducing SNCA expression
#1741Method of Preparing Oligonucleotide Compounds
#1742Method for screening splicing variants or events
#1743RNA-editing oligonucleotides and uses thereof
#1744Modified gapmer oligonucleotides and methods of use
#1745Immunostimulatory oligonucleotides
#1746Compositions and methods for treatment of cardiac diseases
#1747Antisense oligonucleotides targeting ATXN3
#1748Anti-C9ORF72 oligonucleotides and related methods
#1749KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1750Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#1751MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
#1752OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
#1753RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
#1754CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
#1755POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#1756COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#1757Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
#1758C/EBP alpha saRNA compositions and methods of use
#1759LAG3 binding peptides
#1760Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#1761USE OF SINGLE-STRANDED ANTISENSE OLIGONUCLEOTIDE IN PREVENTION OR TREATMENT OF GENETIC DISEASES INVOLVING A TRINUCLEOTIDE REPEAT EXPANSION
#1762METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#1763Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
#1764OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
#1765Modulating apolipoprotein (a) expression
#1766OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1767Compositions for modulating SOD-1 expression
#1768Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#1769Modified RNAi agents
#1770ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
#1771Oligonucleotides for inducing paternal UBE3A expression
#1772Serum amyloid P component (APCS) iRNA compositions and methods of use thereof
#1773COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1774ANTI-TNF COMPOUNDS
#1775Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
#1776ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
#1777OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#1778High Specificity Genome Editing Using Chemically Modified Guide RNAs
#1779Conjugates and preparation and use thereof
#1780Methods for treating hepatitis B infection
#1781Methods for treating hepatitis B infection
#1782RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)
#1783ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS
#1784GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#1785MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
#1786Multiplexed analysis of materials for tissue delivery
#1787Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1788Engineered producer cell lines and methods of making and using the same
#1789METHODS FOR THE PRODUCTION OF STERILE FISH AND OTHER EGG-PRODUCING AQUATIC ANIMALS AND COMPOUNDS FOR USE IN THE METHODS
#1790Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
#1791Compositions and their uses directed to huntingtin
#1792CANCER TREATMENT
#1793RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
#1794STEREODEFINED SUB-MOTIF OPTIMISATION METHODS
#1795Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
#1796HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1797Composition for delivery of genetic material
#1798Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
#1799Oligonucleotide compounds for targeting huntingtin mRNA
#1800Combinations for the modulation of SMN expression